moneyheap
COO · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is The Cooper Companies, Inc. Common Stock (COO) stock moving?
The main story is a leadership change. On Oct 27 the CEO left effective immediately, Executive Chair Walt Rosebrough took over day-to-day operations, and a search for a permanent CEO began. The company said recent performance has not met expectations and announced board refreshment, including Shlomi Nachman joining on Dec 8 and three directors not seeking reelection in 2027. Full-year 2026 guidance was reaffirmed, which limits the negative read. The stock fell 2.1% to 59.88 on Oct 27, dipped to 59.41 on Oct 28 on 4.24M shares, and recorded its heaviest volume in the window on Oct 30 (7.89M, about 2.8 times the 14-day average of roughly 2.8M, close 59.55). It then rallied to 64.42 on Nov 4 (+5.9%), a move the provided news does not explain. It has since held between 62.36 and 63.93 and closed at 63.57 on Nov 10, about 4% above the Oct 26 close of 61.14. The next catalyst is the Dec 3 results, and the CEO appointment timing is unknown.
News behind the analysis
- CooperCompanies Announces Leadership Transition and Board RefreshmentAl White stepped down as President and CEO effective immediately, and independent director Walt Rosebrough became Executive Chair. The company reaffirmed fiscal 2026 guidance and said a CEO search is underway.
- CooperCompanies Announces Date for Fourth Quarter and Full Year 2026 Financial ResultsThe company will release fourth quarter and full year 2026 results on December 3, 2026, the next major scheduled catalyst.
About The Cooper Companies, Inc. Common Stock
The Cooper Companies (CooperCompanies) is a global medical device maker based in San Ramon, California, with two businesses: CooperVision, which makes contact lenses, and CooperSurgical, which sells fertility and women's health products. It stands out for its focus on daily disposable lenses such as MyDay and for myopia-control products for children such as MiSight. It has recently drawn attention because it cut US distributor inventory, its CEO announced he was stepping down in October 2026, and law firms have opened shareholder investigations.
How it makes money
About two-thirds of revenue (roughly $724M of about $1.08B in the fiscal Q2 2026 quarter) comes from CooperVision. That unit sells soft contact lenses, mainly daily, monthly and specialty lenses, plus myopia-management products, to eye-care professionals, distributors and retailers around the world. The remaining third or so comes from CooperSurgical, which sells fertility products and services (IVF lab media and equipment, genetic testing) and office and surgical products for women's health. The company expects full-year revenue of roughly $4.3B for fiscal 2026.
What usually moves COO
- Contact lens market growth and shift to premium daily lenses
- Distributor inventory levels and US channel destocking
- Fertility/IVF demand and litigation over the embryo culture media recall
- CEO transition and execution on margins and free cash flow
- Currency swings and Asia-Pacific demand